RESUMEN
Meconium-stained amniotic fluid (MSAF) presents a complex medical scenario with significant implications for maternal and neonatal health. This case report explores the intricacies surrounding MSAF, focusing on its diagnosis, treatment, and the associated meconium aspiration syndrome (MAS). The report emphasizes the critical role of antibiotic prophylaxis in lower segment cesarean sections (LSCS) in balancing infection prevention in the mother with neonatal considerations. Additionally, it highlights personalized pain management and post-operative care regimens, contributing to a comprehensive strategy for maternal and neonatal well-being. A 27-year-old primigravida (primi) underwent a cesarean section due to the presence of meconium in the amniotic fluid, indicating fetal distress. The report meticulously documents vital signs, laboratory findings, and the timeline of events. The case report underscores the importance of diagnosing and treating MAS, offering valuable insights into management strategies and their impact on maternal and neonatal health. This case report emphasizes the critical role of antibiotic prophylaxis in LSCS to prevent maternal infection while considering neonatal well-being. The personalized pain management approach and post-operative care regimens contribute significantly to a comprehensive strategy for maternal and neonatal well-being. The findings provide valuable insights into diagnosing and treating MAS, highlighting the importance of timely intervention in similar clinical scenarios.
RESUMEN
The gut-brain axis (GBA) represents a complex bidirectional communication system linking the gastrointestinal tract with the CNS, influencing various physiological processes, including cognition. Emerging research suggests a significant interplay between diabetes mellitus (DM) and Alzheimer's disease (AD) mediated through this axis. DM, characterized by impaired insulin signaling and chronic inflammation, appears to exacerbate the pathology of AD. Key mechanisms include insulin resistance affecting neuronal function and promoting amyloid-beta accumulation and tau phosphorylation, hallmark features of AD. Additionally, dysbiosis of gut microbiota in DM may contribute to neuroinflammation and oxidative stress, further aggravating AD pathology. The gut microbiota can modulate systemic inflammation and metabolic dysfunction, potentially impacting AD progression in DM individuals. Understanding these interactions is crucial for developing targeted therapeutic strategies that address both DM and AD simultaneously. This abstract highlights the intricate relationship between metabolic disorders like DM and neurodegenerative conditions such as AD, emphasizing the role of the GBA as a pivotal area for future research and therapeutic interventions.
RESUMEN
A series of resveratrol surrogate molecules were designed, synthesized and biologically evaluated for inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) along with anti-oxidant activity as potential novel multifunctional agents against Alzheimer's disease (AD). Six novel compounds were synthesized by reacting (E)-4-(3,5-Dimethoxystyryl) aniline with benzaldehyde and some selected derivatives of benzaldehyde in the presence of ethanol and a few drops of glacial acetic acid which followed the general scheme involved in the formation of Schiff bases. The spectral analysis data including FT-IR, 1H-NMR, 13C-NMR, and Mass spectroscopy results were found to be in good agreement with the newly synthesized compounds (Resveratrol Surrogate Molecules 1-6). The synthesized compounds were evaluated for their dual cholinesterase inhibitory activities, cytotoxic effect, and anti-oxidant potential. The results showed that compound RSM5 showed potent inhibitory activity against AChE and BChE. In, addition the cytotoxicity of the compound RSM5 is less and found to be within the desirable limit indicating the potential safety of RSM5. Also, it possesses substantial anti-oxidant activity which qualifies RSM5 as an anti-AD agent. Taken together, these findings demonstrate that the molecule RSM5 had the most multifunctional properties and could be a promising lead molecule for the future development of drugs for Alzheimer's treatments.
